Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment
Ophthalmology Retina · 2026
DOI: 10.1016/j.oret.2026.04.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2026. Verfasst von Itay Nitzan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. E…. Hauptthemen laut MEDLINE: Retinal Detachment, Vitreoretinopathy, Proliferative, Tetracyclines, Visual Acuity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: To evaluate the association between documented systemic tetracycline administration and the risk of proliferative vitreoretinopathy (PVR)-related outcomes after rhegmatogenous retinal detachment (RRD). DESIGN: Retrospective cohort study with 1-year follow-up. PARTICIPANTS: Adults aged 18 years or older with RRD were identified within a multicenter federated electronic health record network. After 1:1 propensity score matching, 2886 patients with documented systemic tetracycline administration were compared with 2886 matched controls. METHODS: Systemic tetracycline exposure was defined as a recorded prescription from 1 month before to 6 months after RRD-related cohort entry. Propensity score matching was performed on demographics, socioeconomic determinants, systemic and ophthalmic comorbidities, medications, laboratory values, and health care utilization. Time-to-event analyses were conducted using Kaplan-Meier estimation and Cox proportional hazards models. Prespecified sensitivity analyses and active comparator analyses were performed to assess robustness. MAIN OUTCOME MEASURES: Hazard ratios (HRs) for PVR-related outcomes, defined as complex retinal detachment repair, nondiabetic proliferative retinopathy, and tractional retinal detachment. Reoperation was evaluated as a secondary outcome. RESULTS: Baseline characteristics were well balanced after matching. During comparable follow-up, systemic tetracycline administration was associated with a lower risk of complex retinal detachment repair (HR, 0.33; 95% confidence interval [CI], 0.25-0.43), nondiabetic proliferative retinopathy (HR, 0.63; 95% CI, 0.45-0.89), and tractional retinal detachment (HR, 0.57; 95% CI, 0.43-0.75). Reoperation was also less frequent among tetracycline-exposed patients (HR, 0.34; 95% CI, 0.26-0.46). Findings remained consistent across prespecified sensitivity analyses, including alternative exposure definitions, follow-up durations, doxycycline-only exposure, and active comparator analyses. E-values suggested robustness to unmeasured confounding, and positive and negative control outcomes supported the internal validity of the observed associations. CONCLUSIONS: Documented systemic tetracycline administration was associated with a lower risk of PVR-related outcomes after RRD. These findings support further prospective evaluation of tetracyclines as a potential adjunctive strategy for PVR prevention. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: itay.nitzan@mail.huji.ac.il.
- Faculty of Medicine, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Zitieren
APA
Nitzan, I., Eshel, Y., Shlomov, T., Kubovsky, S., Shemesh, N., Levy, J., Chowers, I., & Khateb, S. (2026). Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2026.04.017
Vancouver
Nitzan I, Eshel Y, Shlomov T, Kubovsky S, Shemesh N, Levy J, et al. Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment. Ophthalmology Retina. 2026. doi:10.1016/j.oret.2026.04.017
BibTeX
@article{Nitzan2026,
author = {Nitzan, Itay and Eshel, Yossi and Shlomov, Tehila and Kubovsky, Shoham and Shemesh, Nadav and Levy, Jaime and Chowers, Itay and Khateb, Samer},
title = {Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment},
journal = {Ophthalmology Retina},
year = {2026},
doi = {10.1016/j.oret.2026.04.017}
}
EUVIMED